Evidence map›Paper›PMID 29299343›Full record

ArticleRMD open2017

Diagnostic spectrum and 2-year outcome in a cohort of patients with very early arthritis.

Ellen Sauar Norli, Gina Hetland Brinkmann, Tore Kristian Kvien, Olav Bjørneboe, Anne Julsrud Haugen, Halvor Nygaard, Cathrine Thunem, Elisabeth Lie, Maria Dahl Mjaavatten

Open access · goldAbstract read
In one paragraph

Article in RMD open, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.4field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Observational
  4. Review
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Ellen Sauar NorliDepartment of Rheumatology, Martina Hansens Hospital, Sandvika, Norway.
Gina Hetland BrinkmannDepartment of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway.
Tore Kristian KvienDepartment of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway.
Olav BjørneboeDepartment of Rheumatology, Martina Hansens Hospital, Sandvika, Norway.
Anne Julsrud HaugenDepartment of Rheumatology, Østfold Hospital Trust, Grålum, Norway.
Halvor NygaardDepartment of Rheumatology, Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway.
Cathrine ThunemDepartment of Rheumatology, Betanien Hospital, Skien, Norway.
Elisabeth LieDepartment of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway.
Maria Dahl MjaavattenDepartment of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway.
Diakonhjemmet Hospital · NOBetanien Hospital · NOMartina Hansens Hospital · NOØstfold Hospital Trust · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo describe the diagnostic spectrum, arthritis persistency and clinical outcomes after 2 years in patients with inflammatory arthritis (IA) of less than 16 weeks' duration.

methodsData from the Norwegian Very Early Arthritis Clinic, a 2-year longitudinal observational study of adults with IA of ≤16 weeks' duration, were used. Exclusion criteria were arthritis due to crystal deposits, trauma, osteoarthritis and septic arthritis. In all patients who had any follow-up information (population A), clinical diagnoses and persistency of arthritis were described. For patients with 2-year follow-up (population B), we also studied other clinical outcomes (disease activity, pain, fatigue, functional disability and health-related quality of life).

resultsIn population A (n=1017) median (25th-75th percentile) duration of joint swelling was 35.0 (13.0-66.5) days, mean (SD) age 45.7 (14.8) years, 55.2% were females and 17.8% anticitrullinated protein antibodies positive. The most common final diagnoses were undifferentiated arthritis (UA) (41.7%), rheumatoid arthritis (RA) (24.1%) and reactive arthritis (18.1%). After 2 years, the arthritis had resolved in 59% of the patients. The remaining 41.0% had persistent disease defined by disease modifying antirheumatic drug (DMARD) use (32.1%) or persistent joint swelling without DMARD use (8.9%). In population B (n=669), all clinical outcomes improved significantly (P<0.001). Baseline joint pain and fatigue were similar across diagnoses.

conclusionsAmong 1017 patients with IA of ≤16 weeks' duration, UA was the most common diagnosis after 2 years, and less than one-fourth were diagnosed with RA. Arthritis resolved without DMARDs in the majority of the patients. All clinical parameters improved significantly over a 2-year course.

Indexed as

early rheumatoid arthritisepidemiologyoutcomes researchsynovitis

Identifiers

PMID29299343
PMCPMC5743896
OpenAlexW2778469674

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.